China CAR-T Cell

On May 11, Macau’s first YESCARTA® CAR-T cell therapy center jointly built by Fosun Kite, a joint venture of Fosun Pharma (600196.SH, 02196.HK), and Macau Kiang Wu Hospital was officially launched. This marks the official entry of China’s first cell therapy drug, YESCARTA® , into Macau, China, providing new treatment options and options for the […]

Leukemia and other blood tumors have always been a huge threat to people’s lives and health. According to statistics, in 2020, the total number of cancer cases and deaths in China was 4.57 million, with leukemia accounting for 62000 and lymphoma accounting for 57000. But blood tumors such as leukemia and lymphoma are not incurable […]

Uncle Xu (pseudonym), who is over seventy years old, was diagnosed with multiple myeloma two years ago due to an accidental fall. As his condition progressed, he was unable to move and various complications plagued him. After recently receiving CAR-T cell therapy at the Hematology Department of the Second Affiliated Hospital of Nanjing Medical University, […]

On November 20, “Science and Technology Innovation Board Daily” mentioned in a report that Heyuan Biotechnology’s CAR-T product has just been approved and is priced at CNY999,000/USD140,000, which is currently the lowest priced among domestic approved products. According to the latest report from Tianjin Radio and Television, the CAR-T therapy (Nagiolenza Injection) developed by Heyuan […]

Recently, Grandma Sun, an 80-year-old woman suffering from acute lymphoblastic leukemia, went to the Department of Hematology of the Second Affiliated Hospital of Anyi University for a review as scheduled. The examination report showed that the elderly woman’s condition continues to be in remission. Since trying the CAR-T cell clinical trial treatment being carried out […]

Multiple myeloma (MM) is a common malignant tumor of the blood system. It is currently incurable. Patients will eventually face the problem of recurrence. As the number of recurrences increases, treatment becomes more difficult, seriously increasing the burden on patients and affecting their quality of life. Although the treatment of multiple myeloma has achieved certain […]

On August 7 2023, a CAR-T cell therapy patient was successfully discharged from the Hematology and Cancer Center of Chongqing University Cancer Hospital. Grandma Li, 85 years old, has become the oldest patient in China to receive CAR-T cell therapy. Five years ago, Grandma Li felt a mass on her left neck and was diagnosed […]

China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO® from IASO Bio.  It’s the first fully-human BCMA-directed chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory […]

Chimeric antigen receptor T cell (CAR-T) therapy is one of the most promising treatment techniques for recurrent and refractory (R/R) acute B-ALL. Among them, CD19 CAR-T therapy is the most commonly used and has a relatively stable effect. It can induce a higher complete remission (CR) rate in patients with poor prognosis and few treatment […]

Accumulating evidence from clinical and preclinical studies shows that Intestinal flora can modulate the effect of T cell-driven cancer immunotherapy. Such as enhancing the effect of immune checkpoint inhibitors. CAR-T cell therapy is genetically engineered from each patient’s own T cells. They are from the patient’s blood. Modified and expanded in the laboratory, and then […]